Matthew Read comments on SHR in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on the next leg of Shaires’ growth in Michael Nelson’s article:

“Ultimately, Shaires will be judged on whether it can consistently secure attractive private investments at sensible valuations and convert that access into NAV-per-share growth,”

Read more here